Anticoagulation therapy is recommended for patients with non-valvular atrial fibrillation
(NVAF) and an increased risk of stroke. Although apixaban showed superiority over warfarin …

Objectives To investigate effects of appropriately and inappropriately dosed
apixaban/rivaroxaban versus warfarin on effectiveness and safety outcomes in patients with …

Objectives Concerns have arisen recently over the relationship between body mass index
(BMI) and outcomes in atrial fibrillation (AF) patients with direct oral anticoagulants (DOACs) …

Background: All evidence regarding benefits and harms of rivaroxaban for stroke prevention
has not been appraised yet. Study Question: What are the comparative effectiveness and …

Abstract Background: Low-dose rivaroxaban (10 mg/day) has been widely used in Asia for
patients with atrial fibrillation (AF), although there is a lack of evidence regarding its …

Importance The comparative effectiveness of rivaroxaban and apixaban, the most frequently
prescribed oral anticoagulants for ischemic stroke prevention in patients with atrial …

Background Low-dose direct oral anticoagulant (DOAC) use is quite prevalent in clinical
practice, but evidence of its effectiveness and safety compared with high-dose DOAC in …

Abstract Background and Aim Obesity affects nearly 650 million adults worldwide, and the
prevalence is steadily rising. This condition has significant adverse effects on cardiovascular …

Safety and efficacy of direct oral anticoagulants (DOAC) in low weight patients with atrial
fibrillation (AF) is unclear due to few low body weight patients enrolled in clinical trials. To …

Purpose We conducted a multicenter real-world study in China to assess the association
between body mass index (BMI) and clinical outcomes in patients with atrial fibrillation (AF) …